Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, re
{{Drugbox | Verifiedfields = changed | verifiedrevid = 461113915 | IUPAC_name = (RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl)phosphonate | image = Fotemustine.svg | image_class = skin-invert-image | width = 200
| tradename = Mustophoran | Drugs.com = | pregnancy_AU = D | pregnancy_US = | pregnancy_category = | legal_AU = S4 | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).